earnings
RO
NASDAQ · ROIV
Roivant Sciences Ltd.
Healthcare · Biotechnology
$40.94
Down-$0.87 (-2.08%)
Updated Sep 11, 2026, 2:20 AM
SID Score
7.2/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 14.83B
- P/E ratio
- -38.83
- Dividend yield
- 0.00%
- 52-week range
- $13.81 – $42.50
- Volume
- 6.54M
- Avg. volume
- 8.16M
Price performance
ROIV price history
1M range · 20 trading sessions · Daily adjusted prices
ROIV closed at $40.94 after 20 trading sessions, up 12.84% for the selected period.
- Last close
- $40.94
- Period change
- +12.84%
- Period low
- $34.18
- Period high
- $41.81
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $41.265 | $41.405 | $40.215 | $40.94 | 6.54M |
| Sep 9, 2026 | $41.39 | $42.275 | $41.0808 | $41.81 | 11.15M |
| Sep 8, 2026 | $39.98 | $42.50 | $38.41 | $41.48 | 24.67M |
| Sep 4, 2026 | $34.20 | $35.145 | $33.88 | $34.93 | 5.24M |
| Sep 3, 2026 | $34.35 | $34.43 | $33.67 | $34.41 | 6.86M |
| Sep 2, 2026 | $34.64 | $35.0365 | $33.43 | $34.18 | 6.2M |
| Sep 1, 2026 | $34.64 | $34.95 | $34.26 | $34.52 | 6.91M |
| Aug 31, 2026 | $34.83 | $35.34 | $34.015 | $34.64 | 39.47M |
| Aug 28, 2026 | $37.01 | $37.13 | $34.685 | $34.71 | 8.76M |
| Aug 27, 2026 | $36.845 | $37.81 | $36.50 | $37.58 | 4.92M |
| Aug 26, 2026 | $36.925 | $36.93 | $36.32 | $36.75 | 5.26M |
| Aug 25, 2026 | $36.82 | $37.29 | $36.31 | $36.47 | 4.48M |
| Aug 24, 2026 | $36.22 | $36.569 | $35.705 | $36.36 | 5.12M |
| Aug 21, 2026 | $37.03 | $37.18 | $36.225 | $36.30 | 6.19M |
| Aug 20, 2026 | $36.91 | $37.55 | $36.68 | $36.84 | 3.13M |
| Aug 19, 2026 | $37.83 | $37.97 | $36.75 | $37.40 | 5.81M |
| Aug 18, 2026 | $35.91 | $37.46 | $35.86 | $37.37 | 6.41M |
| Aug 17, 2026 | $36.22 | $37.19 | $35.65 | $36.24 | 7.73M |
| Aug 14, 2026 | $36.135 | $36.49 | $35.87 | $36.20 | 4.53M |
| Aug 13, 2026 | $36.70 | $36.70 | $35.78 | $36.28 | 6.03M |
Latest ROIV news
The latest Smart Investors Daily articles mentioning ROIV.
Stock researchResearch & News · Competitors
Loading stock research…